226 related articles for article (PubMed ID: 23078769)
1. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
Petoumenos K; Worm SW; Fontas E; Weber R; De Wit S; Bruyand M; Reiss P; El-Sadr W; Monforte AD; Friis-Møller N; Lundgren JD; Law MG;
J Int AIDS Soc; 2012 Oct; 15(2):17426. PubMed ID: 23078769
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk prediction in HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models.
Krikke M; Hoogeveen RC; Hoepelman AI; Visseren FL; Arends JE
HIV Med; 2016 Apr; 17(4):289-97. PubMed ID: 26268806
[TBL] [Abstract][Full Text] [Related]
3. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.
Friis-Møller N; Thiébaut R; Reiss P; Weber R; Monforte AD; De Wit S; El-Sadr W; Fontas E; Worm S; Kirk O; Phillips A; Sabin CA; Lundgren JD; Law MG;
Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):491-501. PubMed ID: 20543702
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
De Wit S; Sabin CA; Weber R; Worm SW; Reiss P; Cazanave C; El-Sadr W; Monforte Ad; Fontas E; Law MG; Friis-Møller N; Phillips A;
Diabetes Care; 2008 Jun; 31(6):1224-9. PubMed ID: 18268071
[TBL] [Abstract][Full Text] [Related]
5. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.
Law MG; Friis-Møller N; El-Sadr WM; Weber R; Reiss P; D'Arminio Monforte A; Thiébaut R; Morfeldt L; De Wit S; Pradier C; Calvo G; Kirk O; Sabin CA; Phillips AN; Lundgren JD;
HIV Med; 2006 May; 7(4):218-30. PubMed ID: 16630034
[TBL] [Abstract][Full Text] [Related]
6. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.
Squillace N; Lorenzini P; Lapadula G; Bandera A; Cozzi-Lepri A; Rusconi S; Puoti M; Castagna A; Antinori A; Gori A; d'Arminio Monforte A;
J Antimicrob Chemother; 2016 Sep; 71(9):2663-9. PubMed ID: 27272727
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.
Petoumenos K; Reiss P; Ryom L; Rickenbach M; Sabin CA; El-Sadr W; d'Arminio Monforte A; Phillips AN; De Wit S; Kirk O; Dabis F; Pradier C; Lundgren JD; Law MG;
HIV Med; 2014 Nov; 15(10):595-603. PubMed ID: 24840675
[TBL] [Abstract][Full Text] [Related]
8. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.
Friis-Møller N; Ryom L; Smith C; Weber R; Reiss P; Dabis F; De Wit S; Monforte AD; Kirk O; Fontas E; Sabin C; Phillips A; Lundgren J; Law M;
Eur J Prev Cardiol; 2016 Jan; 23(2):214-23. PubMed ID: 25882821
[TBL] [Abstract][Full Text] [Related]
9. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.
Achhra AC; Mocroft A; Reiss P; Sabin C; Ryom L; de Wit S; Smith CJ; d'Arminio Monforte A; Phillips A; Weber R; Lundgren J; Law MG;
HIV Med; 2016 Apr; 17(4):255-68. PubMed ID: 26216031
[TBL] [Abstract][Full Text] [Related]
10. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
; Sabin CA; d'Arminio Monforte A; Friis-Moller N; Weber R; El-Sadr WM; Reiss P; Kirk O; Mercie P; Law MG; De Wit S; Pradier C; Phillips AN; Lundgren JD
Clin Infect Dis; 2008 Apr; 46(7):1101-10. PubMed ID: 18461712
[TBL] [Abstract][Full Text] [Related]
11. Safety and Effectiveness of Highly Active Antiretroviral Therapy in Treatment-Naïve HIV Patients: Preliminary Findings of a Cohort Event Monitoring Study in Belarus.
Setkina S; Dotsenko M; Bondar S; Charnysh I; Kuchko A; Kaznacheeva A; Kozorez E; Dodaleva A; Rossa N
Drug Saf; 2015 Apr; 38(4):365-72. PubMed ID: 25808626
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
13. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.
Worm SW; Sabin CA; Reiss P; El-Sadr W; Monforte Ad; Pradier C; Thiebaut R; Law M; Rickenbach M; De Wit S; Lundgren JD; Friis-Møller N
Diabetes Care; 2009 Mar; 32(3):474-80. PubMed ID: 19056612
[TBL] [Abstract][Full Text] [Related]
14. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.
Capeau J; Bouteloup V; Katlama C; Bastard JP; Guiyedi V; Salmon-Ceron D; Protopopescu C; Leport C; Raffi F; Chêne G;
AIDS; 2012 Jan; 26(3):303-14. PubMed ID: 22089377
[TBL] [Abstract][Full Text] [Related]
15. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
Weber R; Sabin CA; Friis-Møller N; Reiss P; El-Sadr WM; Kirk O; Dabis F; Law MG; Pradier C; De Wit S; Akerlund B; Calvo G; Monforte Ad; Rickenbach M; Ledergerber B; Phillips AN; Lundgren JD
Arch Intern Med; 2006 Aug 14-28; 166(15):1632-41. PubMed ID: 16908797
[TBL] [Abstract][Full Text] [Related]
16. Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.
Hatleberg CI; Ryom L; d'Arminio Monforte A; Fontas E; Reiss P; Kirk O; El-Sadr W; Phillips A; de Wit S; Dabis F; Weber R; Law M; Lundgren JD; Sabin C;
HIV Med; 2018 Oct; 19(9):605-618. PubMed ID: 30019813
[TBL] [Abstract][Full Text] [Related]
17. Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients.
Freitas P; Carvalho D; Souto S; Santos AC; Xerinda S; Marques R; Martinez E; Sarmento A; Medina JL
BMC Infect Dis; 2011 Sep; 11():246. PubMed ID: 21933422
[TBL] [Abstract][Full Text] [Related]
18. Estimated risk of cardiovascular disease among the HIV-positive patients aged 40 years or older in Taiwan.
Wu PY; Chen MY; Sheng WH; Hsieh SM; Chuang YC; Cheng A; Pan SC; Wu UI; Chang HY; Luo YZ; Yang SP; Zhang JY; Sun HY; Hung CC
J Microbiol Immunol Infect; 2019 Aug; 52(4):549-555. PubMed ID: 31036484
[TBL] [Abstract][Full Text] [Related]
19. [Incidence of strokes in HIV-positive patients treated with long term antiretroviral treatment].
Mapoure YN; Nkongni IN; Luma HN; Ngahane BH; Barla E; Ngwane S; Mouelle AS; Njamnshi AK
Pan Afr Med J; 2016; 24():45. PubMed ID: 27642386
[TBL] [Abstract][Full Text] [Related]
20. Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study.
Petoumenos K; Kuwanda L; Ryom L; Mocroft A; Reiss P; De Wit S; Pradier C; Bonnet F; Phillips A; Hatleberg CI; d'Arminio Monforte A; Weber R; Sabin CA; Lundgren J; Law MG;
J Acquir Immune Defic Syndr; 2021 Apr; 86(5):579-586. PubMed ID: 33351531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
